Every October the country turns pink, and the message — on posters, social feeds and waiting-room leaflets — is reassuringly simple: check your breasts and attend your mammogram. The scale of the problem is not in dispute. Breast cancer is the UK’s most common cancer, with around 59,400 new cases and roughly 11,200 deaths a year.¹
What I want to question this month is not whether breast cancer matters — it plainly does — but why a campaign about awareness has become so selective about what women are made aware of. In public messaging, mammography has been promoted from one imperfect test into something close to a synonym for breast health. It is not. A mammogram does not prevent breast cancer. It looks for a cancer that already exists, in tissue clear enough to see it, at the moment the image is taken. Everything outside those three conditions sits in a blind spot — and that blind spot is far larger than most women are ever told.
For further context, see our article on mammography and breast cancer screening.
The 1,300 figure and the half of the sentence that gets left out
If you have read any screening material this month, you have probably seen the claim that breast screening prevents around 1,300 breast cancer deaths a year in the UK. That number is genuine. It comes from the 2012 Independent UK Panel on Breast Cancer Screening, chaired by Professor Sir Michael Marmot — the most authoritative British review of the question.²
What is almost never quoted alongside it is the same panel’s other headline finding: that the programme overdiagnoses around 4,000 women every year.² From New England Journal of Medicine data for every 2,500 women screened for 10 years, 1 breast cancer death would be avoided, about 1,000 women would have false positives and 5 to 15 would be overdiagnosed (Baum, 2010).
Overdiagnosis is not a false alarm. It is a real cancer, confirmed under the microscope, that would never have caused symptoms or shortened a woman’s life had it not been found. Because nobody can tell which individual screen-detected cancers fall into that category, all of them are treated — with surgery, frequently radiotherapy, sometimes years of endocrine therapy.
The panel estimated that overdiagnosed cases make up around 19% of cancers diagnosed in women aged 50–69 during the screening period:² roughly three women overdiagnosed for every one whose life is saved.
10,000 women invited to UK screening from age 50, for 20 years:
- 681 cancers found.
- 129 of them overdiagnosed.
- 43 breast cancer deaths prevented.
Independent UK Panel on Breast Cancer Screening, Lancet, 2012.
Put another way, the panel calculated one breast cancer death prevented for every 235 women invited, or every 180 who attend.² I want to be fair to the panel: having weighed all of this, it concluded that the programme’s benefits outweigh its harms.² But it also described its own overdiagnosis figures as best estimates from inadequate data, and it was emphatic that women deserve clear information on both sides before deciding whether to attend.² Fourteen years later, the pink-ribbon version of the story still mostly delivers one side.
The trials that don’t fit on a poster
The Marmot review is the favourable reading of the evidence. Others are considerably less so.
The Cochrane review by Gøtzsche and Jørgensen, drawing on around 600,000 women in the randomised trials, concluded that if screening reduces breast cancer mortality by 15% and overdiagnosis runs at 30%, then for every 2,000 women invited over ten years, one avoids dying of breast cancer, ten healthy women are treated unnecessarily, and more than 200 experience significant psychological distress from false-positive findings — anxiety and uncertainty that can persist for years.³ The trials with adequate randomisation found no effect on all-cause mortality after 13 years.³
The Canadian National Breast Screening Study is starker still. Nearly 90,000 women aged 40–59 were randomised to five annual mammograms or to physical examination and usual care, then followed for 25 years. By the end, 180 women in the mammography arm and 171 in the control arm had died of breast cancer — a hazard ratio of 1.05, meaning no mortality benefit at all.⁴
Meanwhile 22% of the screen-detected invasive cancers were judged to be overdiagnosed: one for every 424 women screened.⁴ The authors attributed the apparently better survival of mammography-detected cancers to lead-time bias, length bias and overdiagnosis rather than to lives genuinely saved, and called for every screening trial to be re-evaluated in light of how far treatment has advanced since they were run.⁴ That last point matters more each year: the better our treatment becomes, the smaller the margin left for early detection to add.
Applying the same scepticism in both directions
The Canadian trial is contested. Radiology bodies disputed its findings on publication, challenging its randomisation and the quality of its early-1980s equipment.⁵
I have to be consistent. I have argued that thermography should not be judged on 1977 analogue equipment. If that argument holds, the same allowance applies to mammography trials run on 1970s and 1980s machines.
But it cuts both ways. The trials that favour mammography were run in the same era, before modern treatment — so the benefit they measured may well have narrowed since.
The honest position: the mortality benefit of population mammography is real but modest, disputed in size, and bought at a cost in overdiagnosis and false alarms that awareness campaigns rarely disclose.
The dense-breast problem women are not told about
Set the mortality debate aside entirely and mammography still has a structural weakness that affects millions of British women directly. On an X-ray, dense glandular tissue and tumours both appear white. In a dense breast, a cancer can be hidden in plain sight.
The size of the effect is not subtle. In a well-known study in the Journal of the National Cancer Institute, mammography’s sensitivity was 80% in women with predominantly fatty breasts but just 30% in women with extremely dense breasts, and the odds of an interval cancer — one diagnosed after a normal screen — were around six times higher.⁶ Dense tissue is present in roughly 40% of women having mammograms,⁸ and around one in ten have very dense breasts.⁷
The UK’s own BRAID trial, published in The Lancet in 2025, shows what that means in practice. More than 9,000 women at NHS screening sites with dense breasts and a normal mammogram were offered additional imaging. Abbreviated MRI and contrast-enhanced mammography found 17–19 additional cancers per 1,000 women — cancers the mammogram had not seen — against the roughly 8 per 1,000 that mammography detects in this group, more than trebling detection.⁷
The authors are careful to note that the trial does not estimate how much of that extra detection is itself overdiagnosis,⁷ and that caveat deserves respect. But the core message is unmissable: in a dense breast, a normal mammogram is a much weaker reassurance than most women assume.
Yet the NHS Breast Screening Programme in England does not routinely record breast density or tell women theirs.⁸˒⁹ In the United States, notification has been a federal requirement since 2024. In March 2026, a group of MPs wrote calling for change, citing an estimate that around 3,500 breast cancers a year among UK women attending screening go undetected because of breast density.⁸
The Government’s position, set out in Parliament in February 2026, is that the UK National Screening Committee is still considering the question, with concerns about anxiety, confusion and capacity if women are told without a pathway to act on it.⁹ The NHS’s own literature does acknowledge that cancers can be missed, and advises women to report symptoms even after a recent normal mammogram.⁹
Dense breasts, in numbers
- Mammographic sensitivity: 80% in fatty breasts, 30% in extremely dense breasts.
- Interval-cancer risk: around six times higher in extremely dense breasts.
- BRAID trial, 2025: abbreviated MRI and contrast mammography found 17–19 extra cancers per 1,000 dense-breasted women after a normal mammogram.
- NHS England: density not routinely recorded or reported to women.
Detection is not prevention
Even when mammography works exactly as intended, what it delivers is a diagnosis. By the time a tumour is large enough to see on an X-ray, it has typically been developing for years. That is not a failing of radiologists; it is simply what a structural test is.
The problem is that Awareness Month messaging quietly lets “found early” stand in for “prevented” — and a woman can attend every screen she is offered and still have done nothing to change her underlying risk.
The programme also leaves whole groups outside its reach by design. NHS screening invites women from 50 until their 71st birthday, every three years. Women under 50 are not screened at all — the gap I wrote about in my previous article (https://substack.com/home/post/p-213038163), where women without a flagged family history can fall outside both referral criteria and the screening age simultaneously.
Add the women with dense breasts, and the women who develop an interval cancer in the three years between rounds, and “have you had your mammogram?” turns out to be a far narrower question than it sounds.
Breast awareness matters more than the campaign implies
Precisely because a normal mammogram is not a guarantee, knowing what is normal for your own breasts is not a fallback — it is a frontline. Breasts change with hormonal cycles, pregnancy, breastfeeding and menopause, so the aim is familiarity rather than a textbook definition of “normal”.
See our guide to good breast health for further information.
See your GP promptly if you notice any of the following, even if your last mammogram was clear:
- A new lump or thickening in the breast or armpit, or a change in breast size or shape.
- Dimpling, puckering, redness or a change in skin texture.
- A change to the nipple, including inversion, a rash or discharge.
- Persistent pain or swelling in one area of the breast.
Where thermography fits — and where it doesn’t
At The Natural Doctor, ThermoCheck®, our standardised breast thermography protocol, reads physiology rather than structure: the vascular and metabolic activity of breast tissue, not the shape of a mass.
Its most important evidence is not about diagnostic accuracy at all. In the largest thermography study ever conducted, Gros and Gautherie followed 1,527 women whose breasts were structurally healthy but whose thermograms were abnormal; 40% developed breast cancer within five years.¹⁰ That is a risk marker, years ahead of anything a structural test can show — which I covered in detail in my previous article.
For a broader discussion, listen to Dr Eccles talking about breast health, or read more about rethinking breast cancer screening and mammograms.
Because it measures heat rather than X-ray density, a thermogram is not obscured by dense tissue in the way a mammogram is. But I want to be precise here: that does not make thermography a validated supplemental screen for dense breasts.
The evidence for finding cancers that mammography misses in dense tissue belongs to contrast-enhanced MRI and contrast mammography, and that is where I direct women who need structural imaging.
ThermoCheck answers a different question — is this breast tissue behaving abnormally, and is that changing over time? — and because it is non-invasive, radiation-free and involves no compression, it can be repeated as often as that question needs asking.
It is not a replacement for mammography or any guideline-recommended screening, which is also the FDA’s stated position,¹¹ and any persistent abnormality should be accompanied by structural imaging.
You can find out more about breast health consultations and the Natural Doctor breast health clinic.
The levers that actually change the odds
Here is the part of the story that should be on every pink poster and almost never is. Cancer Research UK estimates that around 23% of UK breast cancers are preventable, with alcohol alone accounting for around 8%.¹ That is prevention in the literal sense — cancers that never occur — which is something no screening test, however good, can offer.
- Alcohol is one of the clearest dose-dependent risk factors for breast cancer; cutting back is one of the most effective single changes a woman can make.
- Healthy body composition and regular movement remain, unglamorously, among the best-evidenced levers on long-term risk, particularly after menopause.
- Vitamin D status is worth knowing and correcting: deficiency is common, testing is inexpensive, and correction costs pennies a day. Read more about getting enough vitamin D.
- Iodine and thyroid status matter for breast tissue health and are simple, low-cost tests.
- Oestrogen metabolism — how efficiently the body processes and clears oestrogen — is shaped by liver health, the gut microbiome, cruciferous vegetable intake and body composition, all of which can be addressed without expensive intervention.
- In my own practice, women with an abnormal ThermoCheck thermogram and structurally normal breasts follow a targeted nutraceutical protocol built around the deficiencies I see consistently in this group. In over 80% of cases the thermogram has normalised at six months. This is an unpublished clinical audit, not a controlled trial, and a normal thermogram is not proof of reduced cancer risk — but set against the Gros and Gautherie data, it is a physiological change I take seriously.
For further information about breast cancer risk and prevention, watch Changing the Game in Breast Cancer Risk.
So — should you go for your mammogram?
I am not telling any woman to ignore her NHS invitation. For many women — particularly those at higher risk — attending will be the right decision, and the panel that read the evidence most favourably concluded the programme does more good than harm overall.
What I am saying is that an invitation is an offer, not an instruction, and that both the Marmot panel and the Cochrane reviewers insisted women should have the full numbers before they decide.
Whatever you choose, these are the questions worth asking:
- Do I have dense breasts? The NHS will not tell you by default, so ask. If you do, a normal mammogram means less than you may think.
- If so, is supplemental imaging appropriate for me? Abbreviated MRI and contrast-enhanced mammography have the strongest current evidence for dense breasts.
- What is my actual risk, beyond family history? Reproductive history, lifestyle, breast density and genetics all count.
- What am I doing about the risk factors I can change? This is the only part of the picture that is genuinely preventive.
The bottom line
Breast Cancer Awareness Month should mean awareness of the whole picture.
Mammography is a detection tool with a real but modest mortality benefit, a real cost in overdiagnosis and false alarms, and a significant blind spot in dense breasts — and none of it is prevention. Women are entitled to know all of that, not just the half that fits on a ribbon.
That, to me, is what “unravelling the mystique” means: not swapping one slogan for another, but going back to the primary studies, reading the actual numbers, and using every tool — mammography, MRI, thermography, and the inexpensive lifestyle changes that actually move risk — for exactly what the evidence shows it can do.
I cannot overstate the latter. It is where I see ThermoCheck Thermography’s best role i.e. in identifying women who have risk and non-invasively normalising those thermal signals. That to my mind, is “how to change the game in breast cancer risk”.
For those of you who want to read more on this important topic I would refer you to my book Changing The Game In Breast Cancer Risk (available on Amazon).
References
- Cancer Research UK. Breast cancer statistics. cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer (accessed October 2026).
- Independent UK Panel on Breast Cancer Screening (Marmot MG, et al.). The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-1786.
- Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6).
- Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348.
- American College of Radiology and Society of Breast Imaging. Public response to the Canadian National Breast Screening Study 25-year follow-up, February 2014.
- Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000;92(13):1081-1087.
- Gilbert FJ, et al. Comparison of supplemental breast cancer imaging techniques — interim results from the BRAID randomised controlled trial. Lancet. 2025;405:1935-1944.
- Members of Parliament, letter to the Secretary of State for Health and Social Care: Informing women of dense breasts after NHS screening (Dense Breast Inform campaign), March 2026.
- UK Parliament. Written question 115193, Breast Cancer: Screening, asked 23 February 2026, and Government answer.
- Gros C, Gautherie M. Breast thermography and cancer risk prediction. Cancer. 1980;45(1):51-56.
- U.S. Food and Drug Administration. Breast Cancer Screening: Thermogram No Substitute for Mammogram. FDA Safety Communication, 25 February 2019.
This article is for general educational purposes and does not constitute individual medical advice. It is not a recommendation to decline NHS breast screening; any decision about screening should be made with your GP. Any woman with a breast symptom, a palpable change, or a family history of breast cancer should speak directly with her GP. Thermography, including ThermoCheck®, is offered at The Natural Doctor as an adjunctive monitoring tool and is not a substitute for mammography or other guideline-recommended breast cancer screening.
